NEW DELHI: Biocon Biologics India Ltd on Wednesday said it has received approval from the Drug Controller General of India for emergency use of its device CytoSorb to reduce pro-inflammatory cytokines levels in critical covid-19 patients admitted in the intensive care unit (ICU).
The subsidiary of Biocon Ltd has been granted licence for emergency use of CytoSorb to treat critical covid-19 patients who are 18 years and above.
The licence will be effective until the pandemic has been brought under control in the country. The device will be of crucial help to doctors treating covid-19 patients who develop Cytokine Release Syndrome, popularly known as a ‘cytokine storm’.